studies

non squamous cell - mNSCLC - L1, pembrolizumab plus SoC vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-189, 2018 0.49 [0.38; 0.64] 0.49[0.38; 0.64]KEYNOTE-189, 201810%616NAnot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-189, 2018 0.56 [0.45; 0.70] 0.56[0.45; 0.70]KEYNOTE-189, 201810%616NAnot evaluable PFS (extension)detailed resultsKEYNOTE-189, 2018 0.48 [0.40; 0.58] 0.48[0.40; 0.58]KEYNOTE-189, 201810%616NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-189, 2018 0.52 [0.43; 0.63] 0.52[0.43; 0.63]KEYNOTE-189, 201810%616NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-189, 2018 3.88 [2.61; 5.79] 3.88[2.61; 5.79]KEYNOTE-189, 201810%616NAnot evaluable objective responses (ORR) (extension)detailed resultsKEYNOTE-189, 2018 3.84 [2.58; 5.70] 3.84[2.58; 5.70]KEYNOTE-189, 201810%616NAnot evaluable AE (any grade)detailed resultsKEYNOTE-189, 2018 4.04 [0.36; 44.82] 4.04[0.36; 44.82]KEYNOTE-189, 201810%607NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.03 [0.73; 1.45] 1.03[0.73; 1.45]KEYNOTE-189, 201810%607NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-189, 2018 1.13 [0.56; 2.28] 1.13[0.56; 2.28]KEYNOTE-189, 201810%607NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-189, 2018 2.19 [1.31; 3.65] 2.19[1.31; 3.65]KEYNOTE-189, 201810%607NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.04 [1.16; 3.59] 2.04[1.16; 3.59]KEYNOTE-189, 201810%607NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.03; 8.00] 0.50[0.03; 8.00]KEYNOTE-189, 201810%607NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 3.01 [0.15; 60.33] 3.01[0.15; 60.33]KEYNOTE-189, 201810%607NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 4.02 [0.21; 76.41] 4.02[0.21; 76.41]KEYNOTE-189, 201810%607NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.00 [0.09; 44.56] 2.00[0.09; 44.56]KEYNOTE-189, 201810%607NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 6.06 [0.34; 109.04] 6.06[0.34; 109.04]KEYNOTE-189, 201810%607NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.00 [0.09; 44.56] 2.00[0.09; 44.56]KEYNOTE-189, 201810%607NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.30; 3.35] 1.00[0.30; 3.35]KEYNOTE-189, 201810%607NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.30; 3.35] 1.00[0.30; 3.35]KEYNOTE-189, 201810%607NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.07 [0.67; 1.71] 1.07[0.67; 1.71]KEYNOTE-189, 201810%607NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.83 [0.78; 4.31] 1.83[0.78; 4.31]KEYNOTE-189, 201810%607NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.00 [0.22; 18.06] 2.00[0.22; 18.06]KEYNOTE-189, 201810%607NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 3.02 [0.36; 25.28] 3.02[0.36; 25.28]KEYNOTE-189, 201810%607NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.79 [0.71; 4.50] 1.79[0.71; 4.50]KEYNOTE-189, 201810%607NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.67 [0.30; 1.48] 0.67[0.30; 1.48]KEYNOTE-189, 201810%607NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.37 [0.89; 6.34] 2.37[0.89; 6.34]KEYNOTE-189, 201810%607NAnot evaluable Lacrimation increased AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.40; 2.51] 1.00[0.40; 2.51]KEYNOTE-189, 201810%607NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.39 [0.84; 2.30] 1.39[0.84; 2.30]KEYNOTE-189, 201810%607NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.17 [0.30; 4.56] 1.17[0.30; 4.56]KEYNOTE-189, 201810%607NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.15 [0.60; 2.21] 1.15[0.60; 2.21]KEYNOTE-189, 201810%607NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.26 [0.48; 3.29] 1.26[0.48; 3.29]KEYNOTE-189, 201810%607NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:48 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 307,165,163,176 - treatments: 873